Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate the use of immunotherapy and PARP inhibition in a population with
incurable advanced breast cancer associated with a germline BRCA mutation or HDR-defect. The
main objective is to examine overall response rate of pembrolizumab (immunotherapy) in
combination with Olaparib (PARP inhibitor) in advanced BRCA-mutated or Homology-directed
repair (HDR)-defect breast cancer.